Roche's Alecensa Granted Accelerated FDA Approval in Lung Cancer This is a new treatment for a type of lung cancer that has spread - including to the brain. 60% of patients with brain mets saw shrinkage of the tumor. 18% had a complete response. On average, these responses lasted 9 months. This is proof that the drug crossed the blood brain barrier. It might be worth considering using for any tumor that shows an overexpression of ALK.
